<DOC>
	<DOCNO>NCT00411515</DOCNO>
	<brief_summary>The purpose prospectively randomize multicentre study prove efficacy safety mycophenolate mofetil ( MMF ) prevent graft rejection improvement clear graft survival follow high-risk keratoplasty . The patient MMF group receive MMF orally 2x1 g daily 6 month . Endpoints immune reaction free clear graft survival occurence side-effects .</brief_summary>
	<brief_title>A Prospective Randomized Trial Mycophenolate Mofetil Risk Penetrating Keratoplasty</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Keratoplasty increase risk immunologic graft rejection abscence risk factor graft failure . ( repeat keratoplasty , steroidresponse , limbokeratoplasty , oversized graft . Normal risk case . HerpesKeratitis . Glaucoma . Limbus stem cell deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>